Prof. Dr. med. Konstanze Döhner

1. General Information

Name, Academic Title:	Konstanze Döhner, Prof. Dr. med.
Date and Place of Birth:	13.10.1964; Mosbach, Germany
Sex:	Female
Office Address:	Department of Internal Medicine III, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany
Phone:	+49-731-500-45501
Fax:	+49-731-500-45505
E-Mail:	konstanze.doehner@uniklinik-ulm.de
Current Position:	Assistant Professor, Department of Internal Medicine III, Ulm University
Children:	Three (8, 10 and 14 years)
Maternity Leave:	01/1998-04/1998, 02/2001-04/2001, and 08/2003-12/2003

2. University Education

06.05.1991	Medical Licensing Examination
1984-1991	Heidelberg University Medical School

3. Academic Degrees

20.10.2005	Professor of Medicine (*außerplanmäßige [Apl] Professorin*), Internal Medicine, Ulm University
21.06.2001	Postdoctoral Thesis (*Habilitation*), Internal Medicine, Heidelberg University, Mentor: Prof. A. Ho
29.04.1993	Doctoral Thesis (*Promotion*), Medicine, Heidelberg University, Advisor: Prof. Dr. med. W. Friedl

4. Professional Experience

Since 04/2000	Attending physician in Internal Medicine, Hematology, Oncology, Rheumatology, Infectious Diseases; Department of Internal Medicine III, Ulm University (Director: Prof. Dr. H. Döhner)
15.05.2003	Board certification in Hematology/Oncology
19.05.1999	Board certification in Internal Medicine
12/1999-03/2000	Fellowship in Internal Medicine, Hematology, Oncology, Rheumatology, Infectious Diseases; Department of Internal Medicine III, Ulm University (Director: Prof. Dr. H. Döhner)
12/1997-09/1999	Fellowship in Internal Medicine, Hematology, Oncology, Rheumatology; Department of Internal Medicine V, Heidelberg University (Director: Prof. A. Ho)
07/1997-11/1997	Postdoctoral Fellowship; Institute of Genetics, The Hospital For Sick Children, Toronto, Canada (Mentor: Prof. S. W. Scherer)
11/1995-06/1997	Postdoctoral Fellowship; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg (Mentor: Prof. P. Lichter)
06/1991-10/1995	Residency/Fellowship in Internal Medicine, Hematology, Oncology, Rheumatology; Department of Internal Medicine V, Heidelberg University (Director: Prof. W. Hunstein)

5. Awards and Honors

2006	Science Award of the city of Ulm
1998	Science Award for Hematologic Research of the Süddeutsche Hämoblastose Gruppe (SHG)

6. Publications

1. Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, KindlerT, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K. Monitoring of minimal residual disease in *NPM1*-mutated acute myeloid leukemia: A study from the German-Austrian AML Study Group (AMLSG). **J Clin Oncol**. 2011;29:2709-16.
2. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CAJ, Wouters BJ, van der Poel-van de Luytgaarde SC, Damm F, Krauter J, Ganser A, Schlenk RF, Löwenberg B, Delwel R, Dohner H, Valk PJM,* Döhner K.* Prognostic impact, concurrent genetic mutations and gene expression features of AML with *CEBPA* mutations in a cohort of 1182 cytogenetically normal AML: further evidence for *CEBPA* double mutant AML as a distinctive disease entity. **Blood**. 2011;117:2469-2475. *Equal contribution.
3. Paschka P, Schlenk R.F, Gaidzik V.I, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst H-A, Germing U, Döhner H, Döhner K. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia (AML) and confer adverse prognosis in cytogenetically normal AML with NPM1 mutation without FLT3-ITD. **J Clin Oncol**. 2010;22:3636-3643.
4. Schlenk RF,* Döhner K,* Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, for the German-Austrian AML Study Group (AMLSG). Prognostic and predictive impact of gene mutations in younger adults with cytogenetically normal acute myeloid leukemia. **N Engl J Med**. 2008;358:1909-1918. *Equal contribution.
5. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics - interaction with other gene mutations. **Blood**. 2005;106:3740-3746.